A groundbreaking injectable medication has demonstrated remarkable effectiveness in reducing cholesterol levels, potentially ...

Factor XIIa inhibitor Andembry (garadacimab) has been cleared in the US for use in patients aged 12 and over with HAE, which ...

Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...

Steqeyma is now supplied as a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, allowing for weight-based dosing for pediatric patients under 60kg.

Celltrion announces US FDA approval of additional presentation of Steqeyma, expanding dosing options for paediatric patients: Incheon, South Korea Tuesday, June 17, 2025, 16:00 Hr ...

Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...

Celltrion's FDA approval of Steqeyma enhances pediatric psoriasis treatment, offering flexible dosing options for children ...

The Phase I trial evaluates the safety, tolerability and preliminary efficacy of ASC50 for the treatment of psoriasis ... development as a once-daily oral tablet and once-monthly subcutaneous ...

Australian biotech CSL has announced that the US Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii), ...

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura ...